These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
70 related articles for article (PubMed ID: 3001292)
21. Biodistribution of the radioprotective drug 35S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR77913). Rasey JS; Grunbaum Z; Krohn KA; Menard TW; Spence AM Radiat Res; 1985 Apr; 102(1):130-7. PubMed ID: 2984715 [TBL] [Abstract][Full Text] [Related]
22. Dose and time relationships of the radioprotector WR-2721 on locomotor activity in mice. Landauer MR; Davis HD; Dominitz JA; Weiss JF Pharmacol Biochem Behav; 1987 Jul; 27(3):573-6. PubMed ID: 2821556 [TBL] [Abstract][Full Text] [Related]
23. Human pharmacokinetics of WR-2721. Shaw LM; Turrisi AT; Glover DJ; Bonner HS; Norfleet AL; Weiler C; Kligerman MM Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1501-4. PubMed ID: 3019968 [TBL] [Abstract][Full Text] [Related]
24. [Investigations on combined injuries, 29th communication. Protective effect of aminopropylamino-ethylthiophosphate (WR 2721) in mice with radiation and combined injuries (irradiation and skin wound or burn) (author's transl)]. Sedlmeier H; Messerschmidt O Strahlentherapie; 1980 Aug; 156(8):572-8. PubMed ID: 6251580 [TBL] [Abstract][Full Text] [Related]
25. Dephosphorylation of WR-2721 with mouse tissue homogenates. Mori T; Nikaido O; Sugahara T Int J Radiat Oncol Biol Phys; 1984 Sep; 10(9):1529-31. PubMed ID: 6090356 [TBL] [Abstract][Full Text] [Related]
26. The protective effect of S-2-(3-aminopropylamino)ethylphosphorothioic acid (WR-2721) on irradiation-induced inhibition of intestinal transport function. Chen TS; Ando M Toxicol Appl Pharmacol; 1983 Sep; 70(3):494-6. PubMed ID: 6314601 [TBL] [Abstract][Full Text] [Related]
27. Normalization of hypercalcemia associated with a decrease in renal calcium reabsorption in Leydig cell tumor-bearing rats treated with WR-2721. Hirschel-Scholz S; Caverzasio J; Rizzoli R; Bonjour JP J Clin Invest; 1986 Jul; 78(1):319-22. PubMed ID: 3013941 [TBL] [Abstract][Full Text] [Related]
28. Loss of high-energy phosphate following hyperthermia demonstrated by in vivo 31P-nuclear magnetic resonance spectroscopy. Lilly MB; Ng TC; Evanochko WT; Katholi CR; Kumar NG; Elgavish GA; Durant JR; Hiramoto R; Ghanta V; Glickson JD Cancer Res; 1984 Feb; 44(2):633-8. PubMed ID: 6581861 [TBL] [Abstract][Full Text] [Related]
29. Protection of mice against fission neutron irradiation by WR-2721 or WR-151327. Steel LK; Jacobs AJ; Giambarresi LI; Jackson WE Radiat Res; 1987 Mar; 109(3):469-78. PubMed ID: 3031721 [TBL] [Abstract][Full Text] [Related]
30. Radioprotective effect of WR-2721 (gammaphos) or cystamine in non-uniform lethal gamma irradiated mice. Kuna P Radiobiol Radiother (Berl); 1986; 27(6):761-9. PubMed ID: 3033737 [No Abstract] [Full Text] [Related]
31. Protection by S-2-(3-aminopropylamino)ethylphosphorothioic acid against radiation-induced leg contractures in mice. Hunter N; Milas L Cancer Res; 1983 Apr; 43(4):1630-2. PubMed ID: 6831410 [TBL] [Abstract][Full Text] [Related]
32. Binding of aminoalkylphosphorothioate radioprotective drugs to rodent tissue proteins. Livesey JC; Grunbaum Z; Krohn KA Biochem Pharmacol; 1990 Jun; 39(11):1807-12. PubMed ID: 2160821 [TBL] [Abstract][Full Text] [Related]
33. Chemical stability and fate of the cytostatic drug ifosfamide and its N-dechloroethylated metabolites in acidic aqueous solutions. Gilard V; Martino R; Malet-Martino M; Niemeyer U; Pohl J J Med Chem; 1999 Jul; 42(14):2542-60. PubMed ID: 10411475 [TBL] [Abstract][Full Text] [Related]
34. Preclinical evaluation of WR-151327: an orally active chemotherapy protector. Green D; Bensely D; Schein P Cancer Res; 1994 Feb; 54(3):738-41. PubMed ID: 8306335 [TBL] [Abstract][Full Text] [Related]
35. In vitro metabolism of the phosphorothioate radioprotectors WR-2721 and WR-3689. Livesey JC; Rasey JS; Vertrees S; Freeman LM; Magee S; Nelson NJ; Chin L; Grunbaum Z; Krohn KA Pharmacol Ther; 1988; 39(1-3):215-7. PubMed ID: 2849127 [No Abstract] [Full Text] [Related]
36. [Investigations with beagles about toxicity and radioprotective effect of the clinical radioprotection substance WR 2721. Part I. Toxicity of WR 2721 (author's transl)]. Wagner M; Sedlmeier H; Wustrow T; Messerschmidt O Strahlentherapie; 1980 Jul; 156(7):486-91. PubMed ID: 6258271 [TBL] [Abstract][Full Text] [Related]
37. Transplacental uptake of WR 2721 by the rat embryo. Davis ME; Conger AD; Sodicoff M Int J Radiat Oncol Biol Phys; 1987 Apr; 13(4):575-8. PubMed ID: 3030982 [TBL] [Abstract][Full Text] [Related]
38. Biological factors affecting the radioprotective efficiency of S-2-[3-aminopropylamino]ethylphosphorothioic acid (WR-2721): LD 50(7) doses. Yuhas JM Radiat Res; 1971 Aug; 47(2):526-9. PubMed ID: 5561940 [No Abstract] [Full Text] [Related]
39. [31P-NMR study of the levels of phosphorus-containing metabolites in the mouse liver during administration of highly dispersed zinc powder]. Fatkullina LD; Dubinskiĭ VZ; Glushchenko NN; Sibel'dina LA; Fedorov IuI Biofizika; 1985; 30(4):650-4. PubMed ID: 4052468 [TBL] [Abstract][Full Text] [Related]
40. Elucidation of the cytoplasmic and vacuolar components in the inorganic phosphate region in the 31P NMR spectrum of yeast. Shanks JV; Bailey JE Biotechnol Bioeng; 1990 May; 35(11):1102-10. PubMed ID: 18592488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]